Last blog added on Friday, May 18th, 2012

Information About The Cross-Border Biotech Blog

Recent Posts

Below is a preview of the five most recent posts from the blog The Cross-Border Biotech Blog. To read these posts in their entirely or subscribe to future updates from this blog, please visit their website!

Friday Science Review: May 18, 2012
May 18th, 2012

The development and application of large scale studies of pathways, metabolites and interactions is clearly hugely important for biomedical advances and today’s paper from the University of Toronto and the University of Ottawa is concerned with acetylomics (a relatively recent addition to the... Read more »

Monday Biotech Deal Review: May 14, 2012
May 14th, 2012

Welcome to your Monday Biotech Deal Review for May 14, 2012.  Highlights from the previous week include the $5 million private placement announced by Lorus Therapeutics and other equity financing announcements, but otherwise the week has generally been a slow one.  Read on to learn more.  Investm... Read more »

Friday Science Review: May 11, 2012
May 11th, 2012

The tumour suppressor p15ink4b is a cyclin-dependent kinase (cdk) inhibitor, which functions to cause cell cycle arrest and whose functional presence in tumour cells is often lost through mutation or deletion. The expression of p15ink4b can be rapidly induced by transforming growth factor beta (TGF-... Read more »

The Partnering Process – Deal Structure: Part 18 of Valuation and Other Biotech Mysteries
May 9th, 2012

[Ed. This is the eighteenth part in Wayne's series. You can access the whole thing by clicking here. Please leave comments or questions on the blog and Wayne will address them in future posts in this series.] Assuming that a partnering deal is signed, what are the usual financial components? Up-fron... Read more »

Monday Biotech Deal Review: May 7, 2012
May 7th, 2012

Welcome to your Monday Biotech Deal Review for May 7, 2012.  Highlights from the previous week include the announcement by Valeant of its agreement to acquire assets from University Medical Pharmaceuticals Corp. for approximately $64M as well as the announcement of Merus’ $10M bought deal private... Read more »

Browse by Province

Clawbies Winners

View the Lawblogs.ca listings for Clawbies Winners.